Full video transcriptClick to expand
Auto-generated transcript of @lifeofrlj's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Alright, here's how you take Milano Tantu, and for anyone who doesn't know what Milano
- 0:03Tantu is, it is a peptide that allows you to get way tanner, way easier, and if you're
- 0:08somebody like me who's naturally very pale, I know I look tan, but I'm naturally like
- 0:12pale white. Milano Tant will help you get tan without using a tanning bed or going outside
- 0:17too much. So I started thinking Milano Tantu two years ago, and the way I started it, the way
- 0:21I was told to do it, is you have to first do a loading phase, so that's for about two weeks,
- 0:26where you start out slow, three units, which is about like 150 micrograms, if you add two
- 0:30mils of backwater to a 10 milligram vial, which is what they usually come in, and then you work
- 0:35your way up. So I went from like three units to four to five to six, all the way up to 10
- 0:41for those two weeks. And I tried to go tanning as much as possible, and then the days I went tanning,
- 0:46I would take the Milano Tantu before tanning, and on the days I didn't go tanning, I would take
- 0:50the Milano Tantu before I went to bed. And eventually I got to a really good looking tan,
- 0:54and then from there I just used a little bit like three to five units before I went to bed,
- 0:58or before I went tanning, maybe like once or twice a month. Currently now I only do about once a month,
- 1:04I'll go to the tanning bed, I'll pay like 20 bucks to get like 12 minutes, and I'll use like
- 1:08again three to five units, and I'm good.
Peptide therapy TikTok claims: separating hype from human data
Quick answer
Melanotan II is a synthetic melanocortin receptor agonist that stimulates melanogenesis through MC1R binding, producing measurable increases in skin pigmentation at doses in the 150-500 microgram range, as documented in human trials. It carries a consistent side effect profile including nausea, flushing, and spontaneous erections, and has been associated in case reports with melanocytic lesion changes when used alongside UV exposure. It holds no regulatory approval for human cosmetic or therapeutic use in the United States or European Union.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Peptide therapy TikTok claims: separating hype from human data, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
SCENESSE (afamelanotide implant) FDA Prescribing Information
Afamelanotide (an alpha-MSH analog) is the only FDA-approved melanocortin peptide of this class, and only to increase pain-free light exposure in erythropoietic protoporphyria, not for cosmetic tanning.
FDA
Afamelanotide for Erythropoietic Protoporphyria
Randomized placebo-controlled trials (NEJM) behind the afamelanotide approval; this is the legitimate human melanocortin evidence, distinct from unapproved tanning peptides.
PubMed
The human peptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging
Anchor review for copper peptide gene-expression and tissue-repair claims.
PubMed
Effects of glycyl-histidyl-lysine-Cu on wound healing
Search-backed PubMed trail for wound-healing claims where specific topical versus injectable context matters.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Peptide therapy TikTok claims: separating hype from human data should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Peptide therapy TikTok claims: separating hype from human data" from RYAN JOHNSON. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Melanotan II is a synthetic melanocortin receptor agonist that stimulates melanogenesis through MC1R binding, producing measurable increases in skin pigmentation at doses in the 150-500 microgram range, as documented in human trials.
The reason this review is not generic is the source wording and the canonical claim label "peptides replying to the jester." In this clip, the useful excerpt is: "Alright, here's how you take Milano Tantu, and for anyone who doesn't know what Milano Tantu is, it is a peptide that allows you to get way tanner, way easier, and if you're somebody like me who's naturally very pale, I know I look tan,..." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against SCENESSE (afamelanotide implant) FDA Prescribing Information (2019), Afamelanotide for Erythropoietic Protoporphyria (2015), and Melanotan II injection resulting in systemic toxicity and rhabdomyolysis (2012), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Melanotan II is a synthetic melanocortin receptor agonist that stimulates melanogenesis through MC1R binding, producing measurable increases in skin pigmentation at doses in the 150-500 microgram range, as documented in human trials.
FormBlends verdict
Peptide social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Melanotan II is a synthetic melanocortin receptor agonist that stimulates melanogenesis through MC1R binding, producing measurable increases in skin pigmentation at doses in the 150-500 microgram range, as documented in human trials. It carries a consistent side effect profile including nausea, flushing, and spontaneous erections, and has been associated in case reports with melanocytic lesion changes when used alongside UV exposure. It holds no regulatory approval for human cosmetic or therapeutic use in the United States or European Union.
- Melanotan II's tanning mechanism is real: Dorr et al. (2000, Journal of Investigative Dermatology) confirmed dose-dependent pigmentation in human subjects via MC1R binding.
- The peptide has no FDA approval for any use. Purchasing it for human use in the US operates outside any regulated pharmaceutical framework.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Melanotan II's tanning mechanism is real: Dorr et al. (2000, Journal of Investigative Dermatology) confirmed dose-dependent pigmentation in human subjects via MC1R binding.
- The peptide has no FDA approval for any use. Purchasing it for human use in the US operates outside any regulated pharmaceutical framework.
- Side effects documented in clinical trials include nausea, facial flushing, fatigue, and spontaneous erections. These were common enough to appear in the original Dorr et al. phase I data.
- Langan et al. (2015, British Journal of Dermatology) published case reports linking Melanotan II use to changes in melanocytic lesions, raising melanoma risk concerns that the creator did not address.
- Tanning beds are classified as Group 1 carcinogens by the International Agency for Research on Cancer. Combining them with a melanocortin receptor agonist has not been studied for long-term safety.
- The creator's dosing math is internally consistent, but no peer-reviewed guideline validates any Melanotan II dosing protocol for cosmetic use in humans.
- Anyone using Melanotan II who notices changes in existing moles or new skin lesions should consult a dermatologist promptly, regardless of whether they believe the peptide caused the change.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @lifeofrlj actually say?
The creator describes a two-week loading protocol for Melanotan II (which they call "Milano Tantu"), starting at roughly 150 micrograms and working up to approximately 500 micrograms daily, timed around tanning bed sessions or taken before bed on off-days. After the loading phase, they report dropping to a maintenance dose of "three to five units" once or twice a month, paired with a single 12-minute tanning bed session.
Their framing is practical and personal: pale skin, difficulty tanning, and a desire to maintain color with minimal UV exposure. They're not pitching this as a medical treatment. They're describing a cosmetic routine. That context matters when evaluating what they got right and what they glossed over.
Does the science back this up?
Partially, but the parts it backs up are also the parts that come with serious safety warnings the creator didn't mention. Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH). It binds melanocortin receptors, primarily MC1R, and does stimulate melanogenesis, meaning it genuinely increases skin pigmentation. That mechanism is real and well-documented.
A 2000 study by Dorr et al. published in the Journal of Investigative Dermatology confirmed that Melanotan II produced dose-dependent increases in skin pigmentation in human subjects. So the core claim, that this peptide increases tanning, is not fabricated.
However, the same research and subsequent pharmacovigilance work have identified consistent side effects: nausea, facial flushing, spontaneous erections in men, and fatigue are among the most commonly reported. Langan et al. (2015, British Journal of Dermatology) flagged concerns about Melanotan II's association with melanocytic lesion changes and potential melanoma risk. The creator mentions none of this.
What did they get wrong (or right)?
Credit where it's due: the dosing math is roughly consistent with what appears in the research literature. Dorr et al. used doses in the range of 0.01 mg/kg, which for an average adult lands near the 500-700 microgram range. Starting low and titrating up is a sensible approach to managing side effects, and the creator's logic of pairing it with UV exposure to activate melanin production is mechanistically sound.
What they got wrong, or more precisely what they omitted, is significant. Melanotan II is not approved by the FDA or any major regulatory body for cosmetic or therapeutic use. It is not legally available as a pharmaceutical product in the United States. The creator doesn't acknowledge this. They also don't mention that changes to existing moles or new lesion growth have been reported by users, a finding serious enough that the British Journal of Dermatology published a case series on it (Langan et al., 2015). Describing a monthly tanning bed session as a casual maintenance routine without noting the compounded UV-plus-melanocortin-receptor stimulation risk is a real gap.
What should you actually know?
Melanotan II has a real pharmacological mechanism and measurable tanning effects. That part of the creator's claim is supported by evidence. But it is an unregulated, unscheduled research compound with no approved human dosing guidelines, no standardized manufacturing oversight, and a side effect profile that includes both short-term issues like nausea and longer-term concerns about melanocytic changes.
The tanning bed component adds another layer of risk. UV exposure is itself a documented carcinogen (IARC Group 1 classification). Combining systemic melanocortin receptor stimulation with UV exposure hasn't been studied in long-term controlled trials. The interaction is not well understood.
- Melanotan II is not FDA-approved. Purchasing it for human use exists in a legal gray area in the US.
- Nausea, flushing, and other side effects are common enough that Dorr et al. documented them in their original 2000 trial.
- Any changes to moles or skin lesions while using Melanotan II warrant prompt dermatological evaluation.
- The creator's casual framing, "once a month, I'll go to the tanning bed," does not reflect the current state of safety evidence.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
RYAN JOHNSON · TikTok creator
346.4K views on this video
Replying to @The Jester
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about melanotan ii's tanning mechanism?
Melanotan II's tanning mechanism is real: Dorr et al. (2000, Journal of Investigative Dermatology) confirmed dose-dependent pigmentation in human subjects via MC1R binding.
What does the video say about the peptide has no fda approval for any use. purchasing?
The peptide has no FDA approval for any use. Purchasing it for human use in the US operates outside any regulated pharmaceutical framework.
What does the video say about side effects documented in clinical trials include nausea, facial flushing,?
Side effects documented in clinical trials include nausea, facial flushing, fatigue, and spontaneous erections. These were common enough to appear in the original Dorr et al. phase I data.
What does the video say about langan et al. (2015, british journal of dermatology) published case?
Langan et al. (2015, British Journal of Dermatology) published case reports linking Melanotan II use to changes in melanocytic lesions, raising melanoma risk concerns that the creator did not address.
What does the video say about tanning beds?
Tanning beds are classified as Group 1 carcinogens by the International Agency for Research on Cancer. Combining them with a melanocortin receptor agonist has not been studied for long-term safety.
What does the video say about the creator's dosing math?
The creator's dosing math is internally consistent, but no peer-reviewed guideline validates any Melanotan II dosing protocol for cosmetic use in humans.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by RYAN JOHNSON, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.